Literature DB >> 19874827

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination.

H Ardon1, B Verbinnen, W Maes, T Beez, S Van Gool, S De Vleeschouwer.   

Abstract

We have successfully treated over two hundred high-grade glioma (HGG) patients with immunotherapy consisting of vaccination with autologous dendritic cells (DCs) loaded with autologous tumour lysate. It has been documented that regulatory T cells (Treg) can counteract anti-tumour immune responses. Therefore, monitoring of Treg in these patients is essential. Up till now, Treg have been characterized based on the expression of the transcription factor Foxp3. Here, we validated IL-7 receptor alpha subunit (CD127)dim expression as a marker for human Treg within HGG patients, as a less laborious assay for routine use in tumour vaccination trials. We noted a strong positive correlation between Foxp3 expression and CD127dim expression in CD4+CD25+ and CD4+ cells. The suppressive function of CD4+CD127dim cells was assessed in an allogeneic mixed lymphocyte reaction (MLR). We conclude that CD127 staining is a fast, well-suited and reproducible Treg monitoring tool in HGG patients treated with immunotherapy. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874827     DOI: 10.1016/j.jim.2009.10.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.

Authors:  Thomas Decker; Gerhard Fischer; Wolfgang Bücke; Philipp Bücke; Frank Stotz; Andreas Grüneberger; Martina Gropp-Meier; Günther Wiedemann; Christine Pfeiffer; Christian Peschel; Katharina Götze
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-04       Impact factor: 4.553

2.  Determination of a CD4+CD25-FoxP3+ T cells subset in tumor-draining lymph nodes of colorectal cancer secreting IL-2 and IFN-γ.

Authors:  Morteza Jafarinia; Fereshteh Mehdipour; Seyed Vahid Hosseini; Leila Ghahramani; Masood Hosseinzadeh; Abbas Ghaderi
Journal:  Tumour Biol       Date:  2016-09-13

3.  Expansion of CD4+CD25+ helper T cells without regulatory function in smoking and COPD.

Authors:  Ester Roos-Engstrand; Jamshid Pourazar; Annelie F Behndig; Anders Bucht; Anders Blomberg
Journal:  Respir Res       Date:  2011-06-08

4.  T-cell epitope finding on EPHA2 for further glioma vaccine development: An immunomics study.

Authors:  Viroj Wiwanitkit
Journal:  J Pediatr Neurosci       Date:  2011-01

5.  Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.

Authors:  Brendan Fong; Richard Jin; Xiaoyan Wang; Michael Safaee; Dominique N Lisiero; Isaac Yang; Gang Li; Linda M Liau; Robert M Prins
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

Review 6.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

Review 7.  Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Authors:  Joost Dejaegher; Stefaan Van Gool; Steven De Vleeschouwer
Journal:  Immunotargets Ther       Date:  2014-03-13

Review 8.  Regulatory T cells in skeletal muscle repair and regeneration: recent insights.

Authors:  Jianhui Wu; Bowen Ren; Daochao Wang; Hui Lin
Journal:  Cell Death Dis       Date:  2022-08-05       Impact factor: 9.685

Review 9.  Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.

Authors:  Giuseppe Nicolò Fanelli; Dario Grassini; Valerio Ortenzi; Francesco Pasqualetti; Nicola Montemurro; Paolo Perrini; Antonio Giuseppe Naccarato; Cristian Scatena
Journal:  Genes (Basel)       Date:  2021-03-20       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.